יחס חוב לטווח קצר להון עצמי: Harmony Biosciences (HRMY)

Harmony Biosciences (HRMY) is a reputable biopharmaceutical player developing effective therapies for orphan diseases of the nervous system. This daily price chart reflects the dynamics of an asset with a value of 0.09. Demand for unique medications is rising due to an expanding list of diagnoses. The brand's financial stability is based on payments from insurance companies and government funds supporting individuals with narcolepsy and cataplexy.

This indicator assesses the company's dependence on short-term liabilities relative to its equity, allowing for the determination of liquidity risk or the degree of aggressive expansion. A stable short-term debt-to-equity ratio confirms the ability of Harmony Biosciences (HRMY) to fund its premium elite pharmacologist fund using internal resources, which minimizes credit shocks and strengthens the fundamental resilience of the business.